Serum syndecan (CD138) levels are increased in patients with symptomatic multiple myeloma compared to normal controls, MGUS, and smoldering myeloma.

被引：0
|
作者：
Kumar, S [1 ]
Ahmann, G [1 ]
Witzig, TE [1 ]
Kyle, RA [1 ]
Greipp, PR [1 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3185
引用
下载
收藏
页码：806A / 807A
页数：2
相关论文
共 50 条
  • [1] Angiogenic cytokines profile in smoldering multiple myeloma: No difference compared to MGUS but altered compared to symptomatic myeloma
    Gkotzamanidou, Maria
    Christoulas, Dimitrios
    Souliotis, Vassilis L.
    Papatheodorou, Athanasios
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    MEDICAL SCIENCE MONITOR, 2013, 19
  • [2] Osteoprotegerin levels are increased in serum of patients with multiple myeloma.
    Corso, A
    Dovio, A
    Sartori, ML
    Rusconi, C
    Klersy, C
    Mangiacavalli, S
    Zappasodi, P
    Varettoni, M
    Angeli, A
    Lazzarino, M
    BLOOD, 2003, 102 (11) : 367B - 367B
  • [3] Serum BCMA levels to predict outcomes for patients with MGUS and smoldering multiple myeloma (SMM).
    Dispenzieri, Angela
    Soof, Camilia M.
    Rajkumar, S. Vincent
    Gertz, Morie A.
    Kumar, Shaji
    Bujarski, Sean
    Kyle, Robert A.
    Berenson, James R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Serum BCMA Levels Predict Outcomes for Patients with MGUS and Smoldering Multiple Myeloma (SMM)
    Dispenzieri, Angela
    Soof, Camilia
    Rajkumar, S. Vincent
    Gertz, Morie A.
    Kumar, Shaji
    Bujarski, Sean
    Kyle, Robert
    Berenson, James
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E312 - E312
  • [5] Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
    A. Visram
    C. Soof
    S. V. Rajkumar
    S. K. Kumar
    S. Bujarski
    T. M. Spektor
    R. A. Kyle
    J. R. Berenson
    A. Dispenzieri
    Blood Cancer Journal, 11
  • [6] Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
    Visram, A.
    Soof, C.
    Rajkumar, S. V.
    Kumar, S. K.
    Bujarski, S.
    Spektor, T. M.
    Kyle, R. A.
    Berenson, J. R.
    Dispenzieri, A.
    BLOOD CANCER JOURNAL, 2021, 11 (06)
  • [7] Osteoprotegerin serum levels in multiple myeloma and MGUS patients compared with age- and sex-matched healthy controls
    A Corso
    A Dovio
    C Rusconi
    M L Sartori
    C Klersy
    M Varettoni
    S Mangiacavalli
    P Zappasodi
    M Ventura
    A Angeli
    M Lazzarino
    Leukemia, 2004, 18 : 1555 - 1557
  • [8] Osteoprotegerin serum levels in multiple myeloma and MGUS patients compared with age- and sex-matched healthy controls
    Corso, A
    Dovio, A
    Rusconi, C
    Sartori, ML
    Klersy, C
    Varettoni, M
    Mangiacavalli, S
    Zappasodi, P
    Ventura, M
    Angeli, A
    Lazzarino, M
    LEUKEMIA, 2004, 18 (09) : 1555 - 1557
  • [9] Characteristics of CD138 expression on plasma cells in multiple myeloma (MM) patients
    Kraj, M.
    Kopec-Szlezak, J.
    Sokolowska, U.
    Poglod, R.
    Kruk, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 111 - 111
  • [10] MUM1 and CD138 Immunophenotype as Prognostic Markers in Patients with Multiple Myeloma
    Junger, A.
    Fibich, C.
    Voralia, M.
    Neufeld, H.
    Doell, H.
    Verma, S. K.
    DeCoteau, J. F.
    Torlakovic, E. E.
    LABORATORY INVESTIGATION, 2009, 89 : 270A - 270A
12345